Key terms
About CARM
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CARM news
Apr 12
1:36am ET
Buy Rating Affirmed: Promising Clinical Data and Strategic Shift Bolster Carisma Therapeutics’ Outlook
Apr 11
8:45pm ET
Promising Future for Carisma Therapeutics’ Cancer Immunotherapy: A Buy Rating Analysis
Apr 11
6:41am ET
Carisma Therapeutics initiated with a Buy at BTIG
Apr 02
6:20am ET
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), Carisma Therapeutics (CARM) and Panbela Therapeutics (OtherPBLA)
Apr 02
6:11am ET
Carisma Therapeutics price target lowered to $9 from $11 at H.C. Wainwright
Apr 02
2:00am ET
Carisma Therapeutics’ Compliance Hurdle: Navigating Anti-Kickback and Fraud Laws in the Pharmaceutical Landscape
Apr 01
8:37am ET
Carisma Therapeutics reports Q2 EPS (52c), consensus (55c)
No recent news articles are available for CARM
No recent press releases are available for CARM
CARM Financials
Key terms
Ad Feedback
CARM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CARM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
